

Please ~~enter~~ this amendment  
do not enter

ESO

### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

#### **Listing of claims:**

Claims 1-69. (Canceled)

Claim 70. (New) A topical pharmaceutical composition, comprising a topically acceptable carrier and a therapeutically effective amount of at least one monocyclic antidepressant for treating a hyperproliferative skin disorder associated with excessive proliferation of skin cells.

Claim 71. (New) The topical pharmaceutical composition according to claim 70, wherein the monocyclic antidepressant is selected from the group consisting of nisoxetine, fluoxetine, norfluoxetine, reboxetine, atomoxetine and vanlafaxine.

Claim 72. (New) The topical pharmaceutical composition according to claim 70, comprising a formulation selected from the group consisting of an ointment, a cream, a gel, a solution, a suspension, a lotion, a shampoo, a foam, a lyposomic formulation, a paste, an emulsion, a salve, suppositories, vaginal tablets, ocular salves or drops, otic drops, nasal spray and nasal drops.

Claim 73. (New) The topical pharmaceutical composition according to claim 72, comprising a formulation selected from the group consisting of a cream, an ointment, a gel, a foam, a solution, and a lotion.

Claim 74. (New) The topical pharmaceutical composition according to claim 70, wherein the hyperproliferative skin disorder is selected from the group consisting of psoriasis, scleroderma, epidermal hyperplasia, hyperkeratosis, acanthosis, papilloma, and actinic keratoses; provided that when the disorder is psoriasis, the cyclic psychotropic agent is not atomoxetine.

Claim 75. (New) The topical pharmaceutical composition according to claim 70, wherein the hyperproliferative skin disorder is a skin cancer selected from the group consisting of basal cell carcinoma, melanoma, squamous cell carcinoma, cutaneous T-cell lymphoma and Kaposi's sarcoma.

Claim 76. (New) The topical pharmaceutical composition according to claim 74, wherein the hyperproliferative skin disorder is psoriasis.

Claim 77. (New) The topical pharmaceutical composition according to claim 71, wherein the monocyclic antidepressant is fluoxetine.